Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
Monthly intravitreal ranibizumab (IVR) during the first 6 month had great effect for macular
edema with branch retinal vein occlusion (BVO) both in visual and anatomical outcome. It is
expected that similar results could be obtained by less frequent IVR. The purpose of this
study is to investigate if IVR by PRN is as effective as by monthly. In addition, the
investigators are going to study the relationship between macular edema and the size and
location of retinal non-perfusion area.